Harvard T.H. Chan School of Public Health suggests combining GLP-1 weight-loss medication with tailored nutrition and ...

Qualigen Therapeutics ( ($QLGN) ) just unveiled an announcement. On July 28, 2025, Qualigen Therapeutics announced a private placement of its ...

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) received two different communications from the staff of the Nasdaq Listing Qualifications office of the Nasdaq Stock Market, LLC. The Company ...

The latest update is out from Qualigen Therapeutics ( (QLGN) ).

A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI. A new cancer drug candidate, developed through a collaboration between ...

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the "Company") received two different communications from the staff of the Nasdaq Listing Qualifications ...

This report provides a comprehensive look at the global market for G protein-coupled receptor (GPCR) targeting technologies.

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

If you are looking to buy fashion accessories like sunglasses, perfumes, and makeup products, you're at the right place.